RELEVIUM

HORIZON Research and Innovation Actions

Granting authority: European Health and Digital Executive Agency. Grant managed through EU Funding & Tenders Portal.

01/09/2022 - 31/08/2026 (4 years)

Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Germany

VIEW PARTNERS >
View website

Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Germany

Johannes Gutenberg-Universitat Mainz, Germany

Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Greece

Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev, Germany

Charokopeio Panepistimio, Greece

Exus Software Monoprosopi Etairia Periorismenis Evthinis, Greece

AINIGMA Technologies, Belgium

MCS DATALABS, Germany

Futuro Perfecto Innovacion SL, Spain

European Cancer Patient Coalition, Belgium

Institut Curie, France

The Health Corporation – RAMBAM, Israel

Sihtasutus Pohja-Eesti Regionaalhaigla, Estonia

Institut Jules Bordet ASBL, Belgium

DBC Europe, Belgium

Pulsify Medical BV, Belgium

CSI Center For Social Innovation LTD, Cyprus

Rozenbaum Konsulting, Bulgaria

Why it matters?

A five-centre randomized clinical trial (RELEVIUM-RCT) will evaluate the efficacy of the proposed personalised care plans for advanced pancreatic cancer patients (n=132) in terms of their QoL. Several secondary outcomes will be investigated, such as the cost-effectiveness of the intervention, its potential in increasing health equity and in relieving the stress burden on the patient families. The study outcomes will result in recommendations for integrating remote monitoring and improving QoL outcomes in palliative care for advanced pancreatic cancer.

What ECPC does

ECPC will contribute to the analysis of the needs and the technology deployment. It will participate in the dissemination and exploitation planning of the project.

EU flag logo

This project is funded by the European Union under Grant Agreement No 101057821.